Rebus Holdings, Inc. (RBSH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rebus Holdings, Inc. (RBSH) trades at $0.0001. Rebus Holdings, Inc. is a biotechnology company focused on developing precision therapeutics for cancer treatment. Their lead asset, RT-AR001, is an adenosine receptor antagonist designed to enhance tumor infiltration. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for RBSH: RBSH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RBSH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on RBSH.
How is this calculated? →Rebus Holdings, Inc. (RBSH) Healthcare & Pipeline Overview
Rebus Holdings, Inc., a biotechnology firm established in 2003, specializes in the research and development of targeted cancer therapies. Their primary focus is RT-AR001, an adenosine receptor antagonist aimed at improving tumor infiltration. Operating in the competitive biotechnology sector, Rebus Holdings seeks to advance precision medicine for cancer treatment.
What Is the Investment Thesis for RBSH?
Rebus Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is currently dependent on the successful development and commercialization of its lead asset, RT-AR001. A key value driver is the potential efficacy of RT-AR001 in enhancing tumor infiltration and improving outcomes in cancer treatment. Upcoming clinical trial results for RT-AR001 will serve as a significant catalyst, potentially driving investor interest and stock appreciation. However, the company faces significant challenges, including the need for substantial capital to fund clinical trials and the risk of clinical trial failures. With a small team and limited resources, Rebus Holdings' ability to compete with larger, more established biotechnology companies is a key consideration. The company's high beta of 10.0 indicates significant volatility, reflecting the speculative nature of its stock.
Based on FMP financials and quantitative analysis
RBSH Key Highlights
Rebus Holdings, Inc. is focused on precision therapeutics for cancer treatment.
- The company's lead asset is RT-AR001, an adenosine receptor antagonist.
- RT-AR001 is designed to enhance tumor infiltration when administered intra-tumorally.
- Rebus Holdings was founded in 2003 and is based in Westlake Village, California.
- The company has a market capitalization of $0.00B, reflecting its early stage of development.
Who Are RBSH's Competitors?
RBSH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RBSH's Key Strengths?
Focus on precision therapeutics for cancer.
- Lead asset, RT-AR001, targets a specific mechanism of action.
- Small, agile team allows for focused research and development.
What Are RBSH's Weaknesses?
Limited financial resources.
- Dependence on the success of a single lead asset.
- Small team may lack the expertise and resources of larger companies.
What Could Drive RBSH Stock Higher?
RBSH catalyst: Clinical trial results for RT-AR001, expected in late 2026, could drive significant investor interest if positive.
- Potential for strategic partnerships with larger pharmaceutical companies to accelerate development and commercialization.
- Expansion of pipeline with new precision therapeutics for cancer treatment.
What Are the Key Risks for RBSH?
Clinical trial failures for RT-AR001 could significantly impact the company's valuation.
- Limited financial resources may hinder the company's ability to fund research and development.
- Competition from larger, more established biotechnology companies.
- Regulatory hurdles and delays could delay the commercialization of RT-AR001.
- The company's reliance on a single lead asset increases its vulnerability to setbacks.
What Are the Growth Opportunities for RBSH?
- Advancement of RT-AR001 through Clinical Trials: The successful completion of clinical trials for RT-AR001 represents a significant growth opportunity for Rebus Holdings. Positive clinical trial results could lead to regulatory approval and commercialization, potentially generating substantial revenue. The market for cancer therapeutics is estimated to reach $200 billion by 2028, providing a large addressable market for RT-AR001. The timeline for this growth opportunity is dependent on the progression of clinical trials, with potential for initial results within the next 2-3 years.
- Expansion of Pipeline with New Precision Therapeutics: Rebus Holdings has the opportunity to expand its pipeline by developing new precision therapeutics for cancer. This could involve targeting different types of cancer or exploring new mechanisms of action. The market for precision medicine is growing rapidly, with increasing demand for personalized treatments. Developing new assets could diversify the company's revenue streams and reduce its reliance on RT-AR001. This growth opportunity could be realized over the next 3-5 years, as the company identifies and develops new therapeutic candidates.
- Strategic Partnerships with Larger Pharmaceutical Companies: Rebus Holdings could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its assets. This could involve licensing agreements, joint ventures, or acquisitions. Partnering with a larger company could provide access to additional funding, expertise, and resources. The timeline for this growth opportunity is uncertain, as it depends on the company's ability to attract potential partners. However, strategic partnerships could significantly enhance the company's growth prospects.
- Exploration of New Delivery Methods for RT-AR001: Rebus Holdings could explore new delivery methods for RT-AR001 to improve its efficacy and reduce side effects. This could involve developing novel formulations or using targeted delivery systems. Improving the delivery of RT-AR001 could enhance its competitive advantage and increase its market potential. The timeline for this growth opportunity is dependent on the company's research and development efforts, with potential for advancements within the next 2-4 years.
- Expansion into New Geographic Markets: Rebus Holdings could expand its operations into new geographic markets to increase its reach and revenue potential. This could involve partnering with local distributors or establishing a presence in key markets. The global market for cancer therapeutics is growing, with significant opportunities in emerging markets. Expanding into new markets could diversify the company's revenue streams and reduce its reliance on the US market. This growth opportunity could be realized over the next 3-5 years, as the company identifies and enters new markets.
What Are RBSH's Competitive Advantages?
- Proprietary technology related to adenosine receptor antagonists.
- Intellectual property protection for its lead asset, RT-AR001.
- Expertise in precision therapeutics for cancer treatment.
What Does RBSH Do?
Founded in 2003, Rebus Holdings, Inc. is a biotechnology company dedicated to the research and development of precision therapeutics for cancer. The company's core focus is on creating innovative treatments that target the specific characteristics of tumors, aiming to improve patient outcomes and reduce the side effects associated with traditional cancer therapies. Rebus Holdings' lead asset is RT-AR001, an adenosine receptor antagonist designed to enhance tumor infiltration and improve the effectiveness of cancer treatments when administered intra-tumorally. Adenosine receptors play a role in suppressing the immune response within tumors, and RT-AR001 aims to block this suppression, allowing the immune system to better target and destroy cancer cells. Based in Westlake Village, California, Rebus Holdings operates with a small team, allowing for focused and agile research and development efforts. The company is committed to advancing its pipeline of precision therapeutics and exploring new approaches to cancer treatment. Rebus Holdings is positioned within the biotechnology industry, which is characterized by rapid innovation, intense competition, and significant regulatory oversight. The company's success depends on its ability to successfully develop and commercialize its lead asset, RT-AR001, and to secure funding for its ongoing research and development activities.
What Products and Services Does RBSH Offer?
- Researches and develops precision therapeutics for cancer treatment.
- Focuses on targeted therapies to improve patient outcomes.
- Develops adenosine receptor antagonists for tumor infiltration.
- Administers treatments intra-tumorally for enhanced effectiveness.
- Aims to reduce side effects associated with traditional cancer therapies.
- Conducts clinical trials to evaluate the safety and efficacy of its therapeutics.
- Seeks regulatory approval for its lead asset, RT-AR001.
How Does RBSH Make Money?
- Focuses on research and development of cancer therapeutics.
- Aims to generate revenue through licensing agreements or partnerships.
- Seeks to commercialize its lead asset, RT-AR001, upon regulatory approval.
What Industry Does RBSH Operate In?
Rebus Holdings, Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation and intense competition. The industry is driven by the increasing demand for novel therapeutics and advancements in precision medicine. Companies in this sector face significant regulatory hurdles and require substantial capital investments to fund research and development. Rebus Holdings is positioned as a developer of precision therapeutics for cancer, targeting a market with significant unmet needs. Competitors include companies like ANTH, CMRA, FPMI, GBIM, and NLVVF, which are also focused on developing innovative cancer treatments. The success of Rebus Holdings depends on its ability to differentiate its lead asset, RT-AR001, and to secure funding for clinical trials and commercialization.
Who Are RBSH's Key Customers?
- Pharmaceutical companies seeking to license or acquire novel cancer therapeutics.
- Healthcare providers who will administer the company's treatments.
- Patients who will benefit from the company's precision therapies.
Key Financial Metrics
Return on equity for Rebus Holdings, Inc. stands at 19.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Rebus Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Westlake Village, US. The company is led by CEO Raul Silvestre. RBSH has traded publicly since 2009.
Financial Health
Rebus Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
RBSH Financials
Bull Case vs Bear Case
Bull Case
- Rebus Holdings is seeing increased chatter about potential partnerships in the AI space, which could significantly expand their market reach and product offerings.
- Recent insider buying activity suggests that those closest to the company believe in its long-term prospects and current valuation.
- The overall community sentiment seems to be shifting towards a more optimistic view of Rebus's strategic direction and ability to innovate.
- Rebus's focus on sustainable solutions is resonating well with environmentally conscious investors, potentially attracting a new wave of capital.
Bear Case
- Concerns linger about Rebus's ability to effectively compete with larger, more established players in the tech industry.
- Some community members express skepticism about the company's ability to deliver on its ambitious growth targets given current market conditions.
- There's a perception that Rebus's marketing efforts are not effectively communicating the value proposition of their products to a wider audience.
- Recent market developments have highlighted potential regulatory hurdles that could impact Rebus's operations and future expansion plans.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RBSH Latest News
No recent news available for RBSH.
RBSH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RBSH.
Price Targets
Wall Street price target analysis for RBSH.
RBSH MoonshotScore
What does this score mean?
The MoonshotScore rates RBSH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Raul Silvestre
Managing Employee
Raul Silvestre is the managing employee of Rebus Holdings, Inc. Information regarding his detailed career history, education, and previous roles is not available in the provided data. As the managing employee, he is responsible for overseeing the company's operations and strategic direction. His leadership is critical to the company's success in developing and commercializing its precision therapeutics for cancer treatment.
Track Record: Due to limited information, Raul Silvestre's specific achievements, strategic decisions, and company milestones under his leadership are unknown. His primary focus is currently on advancing the development of Rebus Holdings' lead asset, RT-AR001, through clinical trials and securing funding for the company's research and development activities.
RBSH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rebus Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity may be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ. Companies in this tier are often early-stage or distressed businesses.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- High risk of fraud or mismanagement.
- Significant price volatility due to low trading volume.
- Potential for delisting or trading suspension.
- Limited regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Obtain and review audited financial statements.
- Assess the company's management team and their experience.
- Evaluate the company's business plan and market opportunity.
- Determine the company's capital structure and funding needs.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Company has been in operation since 2003.
- Focus on research and development of cancer therapeutics.
- Lead asset, RT-AR001, targets a specific mechanism of action.
What Investors Ask About Rebus Holdings, Inc. (RBSH) — Healthcare
What does Rebus Holdings, Inc. do?
Rebus Holdings, Inc. is a biotechnology company focused on the research and development of precision therapeutics for cancer treatment. Their primary focus is on developing targeted therapies that improve patient outcomes and reduce the side effects associated with traditional cancer treatments.
What do analysts say about RBSH stock?
As of March 16, 2026, there is no available analyst coverage for Rebus Holdings, Inc. due to its OTC listing and small market capitalization. The company's valuation is primarily based on the potential success of its lead asset, RT-AR001, and its ability to secure funding for clinical trials and commercialization.
What are the main risks for RBSH?
The main risks for Rebus Holdings, Inc. include the potential for clinical trial failures for its lead asset, RT-AR001, which could significantly impact the company's valuation. The company also faces risks related to limited financial resources, competition from larger biotechnology companies, and regulatory hurdles and delays. Additionally, the company's reliance on a single lead asset increases its vulnerability to setbacks.
What are the key factors to evaluate for RBSH?
Evaluate RBSH on fundamentals, analyst consensus, and risk factors. Rebus Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does RBSH data refresh on this page?
RBSH's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RBSH's recent stock price performance?
Rebus Holdings, Inc. (RBSH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on precision therapeutics for cancer. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RBSH overvalued or undervalued right now?
Rebus Holdings, Inc. (RBSH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RBSH before investing?
Before investing in Rebus Holdings, Inc. (RBSH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available for Rebus Holdings, Inc.
- OTC market investments carry higher risk than exchange-listed stocks.